ANAVEX LIFE SCIENCES CORP (AVXL)

US0327973006 - Common Stock

11.18  +2.55 (+29.55%)

After market: 11.26 +0.08 (+0.72%)

ANAVEX LIFE SCIENCES CORP

NASDAQ:AVXL (12/23/2024, 8:00:00 PM)

After market: 11.26 +0.08 (+0.72%)

11.18

+2.55 (+29.55%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%0%
Sales Q2Q%N/A
CRS94.66
6 Month164.93%
Overview
Earnings (Last)08-06 2024-08-06/bmo
Earnings (Next)12-23 2024-12-23/bmo
Ins Owners3.05%
Inst Owners31.82%
Market Cap948.06M
Shares84.80M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts82.22
Short Float %23.95%
Short Ratio15.02
IPO04-13 2006-04-13
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

AVXL Daily chart

Company Profile

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. The company is headquartered in New York City, New York and currently employs 40 full-time employees. The company went IPO on 2006-04-13. The firm is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The firm analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). The Company’s product candidates include NAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist.

Company Info

ANAVEX LIFE SCIENCES CORP

630 5Th Avenue, 20Th Floor

New York City NEW YORK 10019

P: 18446893939

CEO: Christopher Missling

Employees: 40

Website: https://www.anavex.com

AVXL News

News Image11 hours ago - Market News VideoNotable Monday Option Activity: GOOGL, BA, AVXL
News Image18 hours ago - Anavex Life Sciences Corp.Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the...

News Image19 hours ago - Anavex Life Sciences Corp.Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease

Blarcamesine: Potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancement Submission based on...

News Image8 days ago - Anavex Life Sciences Corp.Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024

Webcast and Conference Call To be Held Monday, December 23, 2024, 8:30 am ET...

News Image15 days ago - Anavex Life Sciences Corp.Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference

Topline data from ATTENTION-AD Open-Label-Extension (OLE) 96/144-Week trial J.P. Morgan 2025 Healthcare Conference, taking place January 13–16, 2025, in...

News Image22 days ago - Anavex Life Sciences Corp.Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024

NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical...

AVXL Twits

Here you can normally see the latest stock twits on AVXL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example